Siegfried Holding
Henrik Kruepper is a seasoned executive with extensive experience in operational and strategic leadership across various sectors, particularly in the chemical and renewable energy industries. Currently serving as Chief Operating Officer for Drug Substances at Siegfried since September 2023, Henrik previously held the position of Chief Executive Officer and Management Board Member at HCS Group, overseeing marketing, sales, procurement, and technology development from May 2012 to August 2023. Prior roles include managing director at Soltecture GmbH, director of sales at Q-Cells AG, and director of strategic marketing and business development at City Solar AG. Henrik’s career also includes significant positions at Evonik Degussa GmbH and Degussa Corporation, focusing on photovoltaics and site excellence. Educational qualifications include a Dipl.-Ing. in Maschinenbau-Verfahrenstechnik from RWTH Aachen University and a diploma from the Emerging Leaders Program at IMD.
Siegfried Holding
1 followers
Siegfried Holding AG is a Switzerland-based life sciences company and active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States and China.